Daniel Zurr, Ph.D.

Chairman of the Board of Directors and Chief Executive Officer

Daniel Zurr Ph.D., CEO, Founder and Chairman of the Board. Dr. Zurr also serves as a Director of QBI, a wholly-owned subsidiary of Quark Pharmaceuticals. Dr. Zurr has extensive experience in senior research and business management in the chemical and pharmaceutical industries.
Prior to establishing Quark, Dr. Zurr was the CEO of Plantex-Ikapharm, then the second largest pharmaceutical company in Israel with more than 300 employees and marketing offices in the United States, Europe and Japan, focused in the field of bulk active ingredients and finished dosage pharmaceuticals. During Dr. Zurr’s tenure, Plantex Ikapharm, now part of the Teva group of companies, became the first Israeli company ever to be inspected and found to be in compliance with US standards for GMP. In the early 1980s, Dr. Zurr served as the Director of Licensing at G.D. Searle in Skokie, Illinois, where he was responsible for the major collaborative agreement between G.D. Searle and Meiji Seika Kaisha (Tokyo), involving the licensing of several drugs and recombinant DNA technology transfer. Dr. Zurr was also responsible for numerous other agreements, including those with Bayer AG (Leverkusen), Ono Pharmaceutical (Osaka) and May and Baker (London). Dr. Zurr received his M.Sc. at the Hebrew University of Jerusalem and his Ph.D. from the Imperial College University of London under the guidance of the Nobel Laureate Professor D.H.R. Barton.

Tomer Natan, LLM, BB, CPA

Chief Financial Officer

Tomer Natan, LLM, BB, CPA, Chief Financial Officer. Mr. Natan possesses over 10 years of finance experience. He joined Quark Pharmaceuticals in 2005. Prior to his current position at Quark, Mr. Natan served as Senior Director of Finance for Quark from 2005 through 2011. Prior to joining Quark, Mr. Natan served as Senior auditor at Ernst & Young Israel. Mr. Natan received his Master of Law from Bar-Ilan University, is a Bachelor of Business specializing in accounting from the College of Management, and is a certified public accountant in Israel.

Shai Erlich, Ph.D.

President US Operations and Chief Medical Officer

Shai Erlich, Ph.D.,CMO. Dr. Erlich joined Quark in 1999 and since then has assumed several executive positions including Director of Portfolio Management and Product Development Strategic Planning. Dr. Erlich completed his studies at the School of Medicine at Ben Gurion University in Israel, and holds an M.Sc. in cancer genetics from the department of Human Genetics, Tel Aviv University, and a Ph.D. in Gene Therapy from the Department of Human Genetics, Mt Sinai Graduate School for Biomedical Sciences at the Mt. Sinai School of Medicine, New York.

Elena Feinstein, MD, Ph.D.

Chief Scientific Officer

Elena Feinstein, MD, PhD., CSO. Dr. Feinstein joined Quark in 1998, and since has held increasingly senior positions, including Director of Research and Development, Vice President of Research and Vice President of Technology Development. Prior to joining Quark, Dr Feinstein worked for 12 years in the Weizmann Institute of Science as Doctoral Fellow, Post-Doctoral Fellow, Scientist and Senior Staff Scientist. She has a 2-year practical clinical experience from Clinical Pediatric Hospital No.1 in Moscow, Russia. Dr. Feinstein obtained her M.D. degree from the 2nd Moscow Medical Institute (Moscow Medical University) and completed her Ph.D. studies (Bondi Prize for Excellence) in the Department of Chemical Immunology, the Weizmann Institute of Science, Rehovot, Israel. Dr. Feinstein has been a leading or senior author of numerous publications in peer-reviewed journals and is named as an inventor on numerous patents.

Juliana Friedmann, M.Sc.

Senior Vice President of Strategy and Planning

Juliana Friedmann, M.Sc., Senior VP of Strategy and Planning. Ms. Friedmann joined Quark (QBI) in 1998. Throughout her career of over 20 years, Ms. Friedmann’s experience has focused on intellectual property, marketing, business development and strategic planning activities in the chemical and pharmaceutical industries. In 1983, Ms. Friedmann joined Dead Sea Bromine, of Israel Chemicals Ltd. (ICL), the largest chemical conglomerate in Israel. From 1983 until she joined Quark in 1998, Ms. Friedmann held a number of progressively senior positions including managing organic fine chemical products serving the life science industries, a major biocide joint venture with the U.S. leader in the field and directing business and new product development activities. Previously Ms. Friedmann worked as a Patent Attorney in Milan, Italy, at one of Italy’s largest patent firms with offices in Germany. Ms. Friedmann received her B.Sc. and M.Sc. degrees in Chemical Engineering from Ben Gurion University, Israel.